Hip lateralisation in children with bilateral spastic cerebral palsy treated with botulinum toxin type A: a 2-year follow-up

Neuropediatrics. 2011 Feb;42(1):18-23. doi: 10.1055/s-0031-1275344. Epub 2011 Apr 15.

Abstract

We investigated the effect of BoNT/A injection on hip lateralisation in children with bilateral spastic cerebral palsy and bilateral adductor spasticity. Pelvic radiographs using Reimers' migration index (MI) were evaluated from 27 children (n=9 females, n=18 males; mean age 5.2 ± 1.96 years; range: 2-10 years; initial MI <50%) with bilateral spastic cerebral palsy over a time period of 2 years. All received injections of BoNT/A (Dysport) every 12 weeks with a dose of 30 Units per kilogram body weight into adductor and medial hamstring muscles on both sides. The MI was calculated before treatment and after 1 and 2 years. The mean MI increased from 25.5% (range: 0-48) to 26.7% (+1.2%, range: 0-79) on the right side and from 28.0% (range: 0-40) to 30.6% (+2.6%, range: 3-84) on the left side over 2 years, respectively. Hips of one patient dislocated bilaterally. The mean MI remained stable over 2 years. Although a specific BoNT/A effect cannot be proven because of the open design of this study, we provide strong evidence that the MI can be kept stable for a time period of 2 years under non-surgical management including therapy with BoNT/A even in CP patients with a high risk for hip dislocation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Botulinum Toxins, Type A / therapeutic use*
  • Cerebral Palsy / diagnostic imaging
  • Cerebral Palsy / drug therapy*
  • Cerebral Palsy / pathology
  • Child
  • Child, Preschool
  • Female
  • Functional Laterality / drug effects
  • Functional Laterality / physiology*
  • Hip / physiopathology*
  • Humans
  • Injections, Intramuscular / methods
  • Longitudinal Studies
  • Male
  • Neuromuscular Agents / therapeutic use*
  • Pain Measurement
  • Statistics, Nonparametric
  • Time Factors
  • Tomography, X-Ray Computed / methods

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A